- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01584765
Rechallenge, Potential Drug Induced Liver Injury (Kaiser)
July 3, 2014 updated by: GlaxoSmithKline
Rechallenge Analysis: Detection of Potential Drug-Induced Liver Injury Using Kaiser California Database
Drug re-administration or rechallenge should be avoided after drug-induced liver injury (DILI) to avoid recurrent and fatal injury.
Rechallenge outcomes vary considerably by drug and patient subjects.
In order to better predict these outcomes, the objective of this analysis is to assess clinical outcomes of positive drug rechallenge following possible drug-induced liver injury.
Electronic medical records from Kaiser Permanente California (KPSC), a managed care organization, will be utilized to identify patients who experience possible drug-induced liver injury following exposure to medications associated with hepatotoxicity, and who are then rechallenged with the medication.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The population was defined as patients 1) 18 years or older at the start of the drug exposure, 2) with 12 months or more of continuous membership plus drug benefit immediately prior to the drug start date, and 3) filling at least one prescription for fourteen drugs associated with hepatotoxicity (Chalasani 2008) anytime between Jan. 1, 2003 to June 30, 2009.
Overall, 1,064,722 patients fulfill these criteria as derived from the total study population of the descriptive analysis.
To be included in this analysis, patients had to be rechallenged with the same suspect drug and had at least one ALT measured at first exposure and during the rechallenge event.
Study observations started in 2002 to allow for a year of pre-study observation in all exposures at risk.
Applying all inclusion and exclusion criteria, the total study population comprises of 846 subjects.
Description
Inclusion Criteria:
- Patients who received at least one prescription for a suspect drug between Jan 1, 2003 and June 30, 2009 (drug initiation period)
Patients who experienced incident DILI event (identified by ALT ≥3xULN or AP ≥2xULN within 6 months of suspect drug administration) during the first exposure period that:
- Resolved to within normal limits of ALT (for hepatocellular & mixed) or AP (for cholestatic) within 180 days or
- Resolved to ALT < 3xULN (for hepatocellular & mixed) within 90 days or AP<2xULN (for cholestatic) within 180 days or
- Dropped by ≥50% of (Peak ALT - ULN) for hepatocellular or of (Peak AP - ULN) for cholestatic or mixed within 180 days
- Patients who were rechallenged with the same suspect drug; rechallenge will include first rechallenge event for the analysis.
- Patients who had at least of 12 months of continuous membership and drug benefit prior to and on the dispensing index date (inclusive). There is no minimum restriction of continuous membership plus drug benefit after the start date.
- Patients who were 18 years of age or older at the time of the first drug dispensing (index date) during the drug initiation period Jan 1, 2003 and June 30, 2009. Each patient's first prescription for the study drugs during the drug initiation period will be identified as index prescription.
- Patients who had health insurance coverage with full medical, pharmacy and lab benefits at the index date.
Exclusion Criteria:
- Patients meeting the definition of chronic liver injury and exhibiting persistent ALT≥3xULN or AP or bilirubin ≥2xULN within 90 days after initial injury
- Patients with chronic liver injury diagnostic codes or included in KPSC disease registries preceding the initial or rechallenge liver injury
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Rechallenge
positive, negative, indeterminate and intermediate rechallenge subtypes
|
14 prescription drugs with known hepatotoxicity : Amoxicillin/clavulanate, nitrofurantoin, isoniazid, trimethoprim-sulfamethoxazole, duloxetine, valproate, interferon-beta, ciprofloxacin, lamotrigine, phenytoin, diclofenac, terbinafine, levofloxacin, aripiprazole
|
Severe positive rechallenge
Subtype of positive rechallenge is defined as: ALT≥5 xULN or AP ≥2 xULN and bilirubin ≥2 xULN with one of the following: INR ≥1.5, Ascites, or Encephalopathy where time from liver chemistry elevation to INR≥1.5,ascites, or encephalopathy is less than 26 weeks in the absence of underlying cirrhosis; other organ failure considered due to DILI; liver-related hospitalization
|
14 prescription drugs with known hepatotoxicity : Amoxicillin/clavulanate, nitrofurantoin, isoniazid, trimethoprim-sulfamethoxazole, duloxetine, valproate, interferon-beta, ciprofloxacin, lamotrigine, phenytoin, diclofenac, terbinafine, levofloxacin, aripiprazole
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Liver injury rechallenge
Time Frame: Up to seven and a half years
|
Liver injury in relation to rechallenge types (positive, negative, indeterminate and intermediate) for hepatocellular, cholestatic and mixed DILI, respectively, defined according to Danan & Benichou, 1993, J Clin Epidemiol, 46(11): p. 1323-30.
|
Up to seven and a half years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severe positive rechallenge
Time Frame: Up to seven and a half years
|
Severe positive rechallenge, defined as: ALT≥5 xULN or AP≥2 xULN and bilirubin≥2 xULN with one of the following: INR≥1.5, Ascites, or Encephalopathy where time from liver chemistry elevation to INR≥1.5,ascites, or encephalopathy<26 weeks in the absence of underlying cirrhosis; other organ failure considered due to DILI; or liver-related hospitalization.
In subjects not meeting the definition of chronic liver injury and exhibiting persistent ALT≥3xULN or AP or bilirubin ≥2xULN after initial injury, positive drug rechallenge is defined as a doubling of ALT, alkaline phosphatase or bilirubin.
|
Up to seven and a half years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
April 12, 2012
First Submitted That Met QC Criteria
April 23, 2012
First Posted (Estimate)
April 25, 2012
Study Record Updates
Last Update Posted (Estimate)
July 8, 2014
Last Update Submitted That Met QC Criteria
July 3, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 115983
- WEUKBRE5538 (Other Identifier: GSK)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug-induced Liver Injury
-
Xi'An Aolitai Pharmaceutical Technology Co LtdRecruitingDrug-Induced Liver Injury | Cholestatic Liver Injury | Mixed Liver InjuryChina
-
Kennon HeardMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.CompletedDrug Induced Liver InjuryUnited States
-
Korea Institute of Oriental MedicineDongGuk University; Korean Medicine Hospital of Pusan National University; Semyung... and other collaboratorsActive, not recruitingDrug Induced Liver Injury | Drug-Induced Kidney Injury | Herbal Medicine Adverse ReactionKorea, Republic of
-
Institute of Liver and Biliary Sciences, IndiaTerminatedDrug Induced Liver InjuryIndia
-
Beijing 302 HospitalUnknownDrug-Induced Liver InjuryChina
-
Beijing 302 HospitalUnknownDrug-Induced Liver InjuryChina
-
Beijing 302 HospitalUnknown
-
Beijing 302 HospitalCompletedDrug-induced Liver Injury,ChronicChina
-
University of Electronic Science and Technology...Chengdu Nuoen Biotechnologies, Inc.; Sichuan Cancer Hospital & InstituteUnknownComparative Study of Circulating microRNA Changes in Patients With Liver Injury and Healthy SubjectsLiver Failure | Drug-Induced Liver InjuryChina
-
Duke UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingDrug Induced Liver InjuryUnited States
Clinical Trials on Prescription drugs with known hepatotoxicity
-
University of MichiganAgency for Healthcare Research and Quality (AHRQ)RecruitingAtrial Fibrillation | Venous Thromboembolism | Pulmonary EmbolismUnited States
-
Centre Hospitalier Universitaire DijonCompletedCommunity InfectionsFrance
-
AbbVieCompletedHepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
-
Karolinska InstitutetWithdrawnSubstance Use Disorders | Benzodiazepine Dependence | Benzodiazepine AbuseSweden
-
University College of Northern DenmarkRecruiting
-
xCuresCancer Commons; Genetic Alliance; LunaDNA; REDCap CloudCompleted
-
University of Wisconsin, MadisonNational Institutes of Health (NIH); National Center for Complementary and...CompletedObesity | OverweightUnited States
-
University Hospital, GrenobleWithdrawnArthritis, Rheumatoid | Biological TherapyFrance
-
Shahid Beheshti University of Medical SciencesEnrolling by invitationConjunctival and Scleral Avascular LesionsIran, Islamic Republic of
-
Guangzhou University of Chinese MedicineFirst Affiliated Hospital, Sun Yat-Sen University; Shanghai 10th People's Hospital and other collaboratorsCompletedAcute Coronary Syndrome | Percutaneous Coronary Artery Intervention | Coronary Artery Bypass Graft